Anti-Mouse CD11b – DyLight® 550

This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This DyLight^® 550 conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.

Next Day 2-8°C

Yellow Laser (563 nm)

B
Depletion
IHC (Frozen)
IHC (Paraffin)
IP
IF Microscopy
For specific conjugates of this clone, review literature for suggested application details.

Clone M1/70 recognizes the α subunit (CD11b) of the mouse CD11b/CD18 complex.

LFA-1α (CD11a) and CD18 are the Integrin alpha-L and beta-2 chains respectively that combine to form LFA-1, a glycoprotein and a member of the Integrin family. Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and for F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. The absence of LFA-1α or ß may induce LAD. The antigen contributes to natural killer cell cytotoxicity, and is involved in various immune phenomena such as leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. The CD11b/CD18 antigen is a heterodimeric surface glycoprotein on leukocytes and belongs to the ß2 integrin family. CD11b functions as a receptor for C3bi complement, clotting factor X, fibrinogen and ICAM-1. CD11c forms an α/ß heterodimeric glycoprotein (CD11c/CD18 complex) which belongs to the ß2 integrin family. The complex binds fibrinogen and reportedly serves as a receptor for iC3b and ICAM-1. During inflammatory responses, it mediates cell to cell interaction and is important in both monocyte adhesion and chemotaxis.

CD11b is expressed on human peripheral blood lymphocytes, NK lymphocytes, monocytes, granulocytes, a subset of T-cells and macrophages.

ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen

1. Springer, T.A., et al. (1978) Eur. J. Immunol. 8:539 2. Springer, T.A., et al. (1982) Immunol. Rev. 68:171 3. Ding, A., et al. (1987) J Exp Med. 165:733 4. Vignali, D. A. et al. (1990) J. Immunol. 144:4030 5. Kantor, A. et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:3320